<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654446</url>
  </required_header>
  <id_info>
    <org_study_id>4522IL/0099</org_study_id>
    <nct_id>NCT00654446</nct_id>
  </id_info>
  <brief_title>IIIb 6 Week Open Label Multicentre Rosuvastatin &amp; Simvastatin</brief_title>
  <official_title>A 6-wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study, Which Describes the Renal Effects of the Lipid-Regulating Agents Rosuvastatin and Simvastatin in the Treatment of Sub's With Fredrickson Type IIa &amp; Type IIb Dyslipidaemia, Inc. Heterozygous Familial Hypercholesterolaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects on the kidney of rosuvastatin and
      simvastatin in subjects with Fredrickson Type IIa &amp; Type IIb Dyslipidaemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Proteinuria</measure>
    <time_frame>2 weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal effects of rosuvastatin and simvastatin</measure>
    <time_frame>2 weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoproteins cholesterol levels</measure>
    <time_frame>2 weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: adverse events &amp; abnormal laboratory markers</measure>
    <time_frame>2 weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>442</enrollment>
  <condition>Fredrickson Type IIa &amp; Type IIb Dyslipidaemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <arm_group_label>2</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting low density lipoprotein level as defined by the protocol.

          -  Fasting triglyceride level as defined by the protocol.

        Exclusion Criteria:

          -  The use of lipid lowering drugs or dietary supplements after Visit 1.

          -  Active arterial disease eg Unstable angina, or recent arterial surgery

          -  Blood creatine levels above the limits defined in the protocol or +4 proteinuria
             during dietary lead in period.

          -  Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Stein</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metabolic &amp; Athersclerotic research centre, Cincinatti, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell Esterline</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2008</study_first_posted>
  <last_update_submitted>March 13, 2009</last_update_submitted>
  <last_update_submitted_qc>March 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Michael Cressman - Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>low density lipoproteins</keyword>
  <keyword>dyslipidaemia</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Crestor</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Zocor</keyword>
  <keyword>Renal</keyword>
  <keyword>kidney</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Lipid Regulating Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

